Targeting KRAS directly has been challenging due to its high affinity for GTP/GDP and lack of suitable binding pockets. However, recent advances have led to the development of specific inhibitors like sotorasib, which targets KRAS G12C mutations. Other strategies include targeting downstream effectors in the RAS/MAPK pathway or employing combination therapies.
